Gyros and GE Healthcare Life Sciences expand Asian distribution relationship to China, Taiwan and Hong Kong
Gyros AB announced that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong. The Gyros platform is used by major biopharmaceutical companies and their service providers to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
Commenting on the announcement, Erik Walldén, CEO at Gyros, said, “The acceptance of our nanoliter-scale immunoassay platform continues to grow within the global biopharmaceutical industry. Expansion into the Asian markets through an experienced and respected network of distributors will ensure the highest possible standards of service and support for customers interested in our products, which we see as one of the key factors for commercial success in this region. Having recently signed with GE Healthcare Japan, we are very pleased to extend our collaboration into China, Taiwan and Hong Kong through such a well-established supplier.”
Other news from the department business & finance
